A new analysis suggests that zanubrutinib may provide better outcomes than ibrutinib as a first-line treatment for patients with chronic lymphocytic leukemia (CLL).
Researchers compared data from two separate Phase 3 clinical trials and adjusted for differences in patient characteristics to create a balanced comparison. The results showed that patients treated with zanubrutinib had a significantly lower risk of disease progression or death than those treated with ibrutinib. In the overall analysis, zanubrutinib reduced this risk by 56%, and after more closely matching patient risk factors between the studies, the reduction increased to 77%.
Although overall survival differences were not statistically significant, survival trends favored zanubrutinib. The findings suggest that second-generation BTK inhibitors such as zanubrutinib may offer greater effectiveness than the older BTK inhibitor ibrutinib.
Researchers noted that while fixed-duration treatment regimens remain important options for CLL, continuous therapy with newer BTK inhibitors continues to be a highly effective frontline approach for many patients.